Houston Methodist Hospital
D

Fatty Liver Disease: Evaluation in the Primary Care Setting

By Houston Methodist Hospital FEATURING David W. Victor III
By Houston Methodist Hospital FEATURING David W. Victor III
3,142 views
September 21, 2021
2 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
25:53
Houston Methodist Hospital

Non-Alcoholic Fatty Liver Disease: Where Are We in 2023?

Feat. N. Gunn
31:07
University of Kansas Medical Center

Risk Stratification and Management of Non-Alcoholic Fatty Liver Dise…

Feat. F. Kanwal
29:32
CME Outfitters

NAFLD/NASH: Current Treatment Strategies

Feat. R. Loomba
32:08
Houston Methodist Hospital

Understanding NASH: Prevention and Treatment

Feat. D. W. Victor III
18:47
Stanford Medicine

Advances in NASH/NAFLD

Feat. N. J. Torok
32:17
Cardiometabolic Health Congress (CMHC)

How and Whom to Screen for NAFLD/NASH? Which Are the High-Risk Group…

Feat. F. Kanwal
36:03
Houston Methodist Hospital

Non Alcoholic Fatty Liver Disease (NAFLD): What’s New and Impact of …

Feat. V. Ankoma-Sey
25:36
University of Texas Southwestern Medical Center

Primary Care Approach to NAFLD

Feat. M. Kubiliun
12:02
Stanford Medicine

Chronic Liver Diseases Q&A

Feat. A. Kwong, N. J. Torok, P. Nkechinyere Dike, P. Y. Kwo, T. Tara Ghaziani, R. Dhanasekaran
21:28
UChicago Medicine: Sixth Annual Updates in Digestive Diseases

Updates in NAFLD/NASH Diagnosis and Management: Pharmacological and …

Feat. M. Charlton
38:17
Cardiometabolic Health Congress (CMHC)

NASH Management 2021 Update: What Is the Effect of Antidiabetic Medi…

Feat. K. Cusi
20:40
Cardiometabolic Health Congress (CMHC)

The Rise of Pediatric Non-Alcoholic Fatty Liver Disease: What Are th…

Feat. S. Xanthakos
09:33
Cardiometabolic Health Congress (CMHC)

2021 NASH Management Update: Do We Have Any Approved Therapies? What…

Feat. C. Mantzoros
29:12
Houston Methodist Hospital

2021 Update on NASH Management: Current and Future Treatment Options

Feat. V. Ratziu
29:13
World Congress Insulin Resistance and Cardiovascular Disease

Lipotoxicity and NAFLD: The Overlooked Complication of T2DM

05:38
University of Colorado Department of Medicine

50 y/o Male With Obesity, Pre-DM, HTN, HLD, Mild AST/ALT 2x ULN, BMI…

Feat. A. Wieland
17:45
Scripps Health

Debate: Which Class of Drug is the Best Treatment for NASH?

Feat. J. Frias, R. Loomba
27:31
CME Outfitters

NAFLD/NASH: Noninvasive Diagnostic Testing

Feat. M. Noureddin
34:59
Cardiometabolic Health Congress (CMHC)

Non-Invasive Assessment of NASH/NAFLD: Can Elastography/Serum-Based …

Feat. R. Loomba
09:22
Cardiometabolic Health Congress (CMHC)

Pediatric NAFLD: What Are the Interventions? What Makes Treatment So…

Feat. S. Xanthakos